Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates

PURPOSE: To evaluate the long-term safety of vascular endothelial growth factor (VEGF) suppression with sustained aflibercept expression after a single intravitreal injection (IVI) of ADVM-022, an anti-VEGF gene therapy, in non-human primates (NHPs). METHODS: Non-human primates received bilateral IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, Szilárd, Oresic Bender, Kristina, Grishanin, Ruslan N., Hanna, Kelly M., Nieves, Julio D., Sharma, Pallavi, Nguyen, Aivan T., Rosario, Romeo J., Greengard, Judith S., Gelfman, Claire M., Gasmi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846953/
https://www.ncbi.nlm.nih.gov/pubmed/33532145
http://dx.doi.org/10.1167/tvst.10.1.34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846953/
https://www.ncbi.nlm.nih.gov/pubmed/33532145
http://dx.doi.org/10.1167/tvst.10.1.34

Ejemplares similares